Screener
AnaptysBio, Inc. ANAB Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219515
| Line item | March 31, 2026(unaudited) | December 31, 2025 |
|---|---|---|
| Accounts payable | $7,517 | $3,871 |
| Accrued expenses | 32,065 | 32,674 |
| Current portion of operating lease liability | 2,120 | 2,080 |
| Total current liabilities | 41,702 | 38,625 |
| Liability related to sale of future royalties | 263,742 | 276,528 |
| Operating lease liability, net of current portion | 11,493 | 12,032 |
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at March 31, 2026 and December 31, 2025, respectively | — | — |
Item 1. Consolidated Financial Statements
FAQ
- What is AnaptysBio, Inc.'s total current liabilities?
- AnaptysBio, Inc. (ANAB) reported total current liabilities of $41.7M in Q1 2026.
- How has AnaptysBio, Inc.'s total current liabilities changed year-over-year?
- AnaptysBio, Inc.'s total current liabilities decreased by 5.3% year-over-year, from $44.04M to $41.7M.
- What is the long-term trend for AnaptysBio, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), AnaptysBio, Inc.'s total current liabilities has grown at a 14.3% compound annual growth rate (CAGR), from $19.82M to $38.63M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about AnaptysBio, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude